May 3, 2011

Green Tea Compound Shows Promise for Leukemia

At the annual meeting of the American Society of Clinical Oncology held in Chicago, researchers from the Mayo Clinic reported results from a Phase II trial which provide additional evidence of clinical activity and low toxicity for epigallocatechin gallate (EGCG, extracted from green tea) in chronic lymphocytic leukemia (CLL) patients.*